Amylyx Pharmaceuticals, Inc.
AMLX
Kedudukan dalam Saham
#4625
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Harga Saham
$26.28
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$3.30B
Perubahan (1 hari)
-4.95%
Perubahan (1 tahun)
75.79%
Negara
US
Perdagangan Amylyx Pharmaceuticals, Inc. (AMLX)
Kategori
Healthcare
EPS untuk Amylyx Pharmaceuticals, Inc. (AMLX)
EPS setakat June 2026 TTM: $-1.41
Menurut laporan kewangan terkini dan harga saham Amylyx Pharmaceuticals, Inc., EPS semasa syarikat (TTM) adalah $-1.41. Pada akhir tahun 2023, syarikat mempunyai EPS sebanyak $0.73 peningkatan berbanding EPS tahun 2022 iaitu $-2.98.
Sejarah EPS untuk Amylyx Pharmaceuticals, Inc. dari 2019 hingga 2026
EPS pada akhir setiap tahun
| Tahun | EPS | Ubah |
|---|---|---|
| 2026 (TTM) | $-1.41 | -68.17% |
| 2024 | $-4.43 | -706.85% |
| 2023 | $0.73 | -124.50% |
| 2022 | $-2.98 | 96.05% |
| 2021 | $-1.52 | 92.41% |
| 2020 | $-0.79 | 203.85% |
| 2019 | $-0.26 | 0.00% |
EPS untuk syarikat atau pesaing yang serupa
| Syarikat | EPS | Perbezaan EPS | Negara |
|---|---|---|---|
| $17.32 | -1,328.37% |
US
|
|
| $-7.98 | 465.96% |
US
|
|
| $-5.29 | 275.18% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,067.38% |
NL
|
